Dr. Kendra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2050 Kenny Rd
Tower 4th Floor
Columbus, OH 43221Phone+1 614-293-4320Fax+1 614-293-2584
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1993 - 1998- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1990 - 1993
Rush Medical College of Rush University Medical CenterClass of 1990
Certifications & Licensure
OH State Medical License 2001 - 2026
NY State Medical License 1998 - 2002
WI State Medical License 1991 - 2001- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer Start of enrollment: 2005 Feb 25
- Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Start of enrollment: 2012 Nov 09
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
- Join now to see all
Publications & Presentations
PubMed
- 604 citationsgp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.Douglas J. Schwartzentruber, David H. Lawson, Jon M. Richards, Robert M. Conry, Donald M. Miller
The New England Journal of Medicine. 2011-06-02 - 74 citationsContinuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trialAlain Algazi, Megan Othus, Adil Daud, Roger S. Lo, Janice M. Mehnert
Nature Medicine. 2020-10-05 - 585 citationsPhase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced MelanomaAntoni Ribas, Richard F. Kefford, Margaret A. Marshall, Cornelis J. A. Punt, John B. A. G. Haanen
Journal of Clinical Oncology. 2013-02-10
Journal Articles
- Prognostic Gene Expression Profiling in Cutaneous MelanomaDouglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Joanne..., JAMA Dermatology
Authored Content
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Press Mentions
AACR Annual Meeting 2023: Therapy Advances for Patients with Rare Melanoma TypesMay 18th, 2023- Desmoplastic Melanoma Patients Respond "Exceptionally" Well to Treatment with Immunotherapy AloneMay 5th, 2023
- Rare Melanoma Very Likely to Respond to Treatment with PembrolizumabMay 5th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
